Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

SAB Biotherapeutics (SABS) Other Accumulated Expenses (2020 - 2026)

SAB Biotherapeutics filings provide 7 years of Other Accumulated Expenses readings, the most recent being $1.0 million for Q1 2026.

  • On a quarterly basis, Other Accumulated Expenses rose 35.68% to $1.0 million in Q1 2026 year-over-year; TTM through Mar 2026 was $1.0 million, a 35.68% increase, with the full-year FY2025 number at $849778.0, up 258.31% from a year prior.
  • Other Accumulated Expenses hit $1.0 million in Q1 2026 for SAB Biotherapeutics, up from $849778.0 in the prior quarter.
  • In the past five years, Other Accumulated Expenses ranged from a high of $1.7 million in Q3 2024 to a low of $64850.0 in Q2 2024.
  • Median Other Accumulated Expenses over the past 5 years was $364478.0 (2023), compared with a mean of $522075.3.
  • Biggest five-year swings in Other Accumulated Expenses: crashed 76.29% in 2024 and later skyrocketed 978.08% in 2025.
  • SAB Biotherapeutics' Other Accumulated Expenses stood at $513110.0 in 2022, then fell by 28.97% to $364478.0 in 2023, then tumbled by 34.93% to $237164.0 in 2024, then surged by 258.31% to $849778.0 in 2025, then increased by 18.64% to $1.0 million in 2026.
  • The last three reported values for Other Accumulated Expenses were $1.0 million (Q1 2026), $849778.0 (Q4 2025), and $649957.0 (Q3 2025) per Business Quant data.